Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MURANASDAQ:NLTXNASDAQ:NVCTNASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMURAMural Oncology$2.48+0.8%$2.60$0.95▼$4.74$42.48M3.361.30 million shs51,390 shsNLTXNeoleukin Therapeutics$17.20-0.1%$17.16$2.03▼$14.36$161.65M1.1150,104 shs238,965 shsNVCTNuvectis Pharma$7.71-0.4%$9.17$4.44▼$11.80$161.72M-0.16129,287 shs166,813 shsPBYIPuma Biotechnology$3.31$3.26$2.23▼$4.13$164.28M1.29437,478 shs258,837 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMURAMural Oncology+0.81%+0.40%-5.70%+110.17%-19.22%NLTXNeoleukin Therapeutics0.00%-6.01%-0.46%+12.20%-46.27%NVCTNuvectis Pharma-0.39%-4.22%-20.19%-26.29%+18.62%PBYIPuma Biotechnology0.00%-2.65%-3.78%+5.41%+5.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMURAMural Oncology3.4754 of 5 stars3.35.00.00.02.71.71.3NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVCTNuvectis Pharma2.9391 of 5 stars3.50.00.00.03.05.00.6PBYIPuma Biotechnology4.1191 of 5 stars3.52.00.00.02.14.23.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMURAMural Oncology 2.60Moderate Buy$13.00424.19% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ANVCTNuvectis Pharma 3.00Buy$17.00120.49% UpsidePBYIPuma Biotechnology 3.00Buy$7.00111.48% UpsideCurrent Analyst Ratings BreakdownLatest MURA, NVCT, NLTX, and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/APBYIPuma Biotechnology$230.50M0.71$0.85 per share3.88$1.88 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMURAMural Oncology-$128.51M-$7.67N/AN/AN/AN/A-83.39%-70.70%8/12/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ANVCTNuvectis Pharma-$19M-$1.13N/AN/AN/AN/A-148.83%-95.60%8/5/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.774.308.71N/A16.37%49.35%18.25%7/30/2025 (Estimated)Latest MURA, NVCT, NLTX, and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMURAMural OncologyN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMURAMural OncologyN/A5.085.08NLTXNeoleukin TherapeuticsN/A15.3315.33NVCTNuvectis PharmaN/A3.283.28PBYIPuma Biotechnology0.111.531.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMURAMural Oncology80.21%NLTXNeoleukin Therapeutics52.37%NVCTNuvectis Pharma96.77%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipMURAMural Oncology2.20%NLTXNeoleukin Therapeutics1.58%NVCTNuvectis Pharma30.52%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMURAMural Oncology11917.27 million16.89 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataNVCTNuvectis Pharma820.89 million14.52 millionNot OptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableMURA, NVCT, NLTX, and PBYI HeadlinesRecent News About These CompaniesFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - NasdaqJune 26 at 10:17 AM | nasdaq.comPuma Biotechnology: Updated Timelines And A Resurgence In SentimentJune 25 at 11:31 AM | seekingalpha.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a BargainJune 24 at 9:50 AM | zacks.comPuma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?June 24 at 4:35 AM | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 8,100 Shares of StockJune 18, 2025 | insidertrades.comBrian M. Stuglik Sells 8,100 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 10,800 Shares of StockJune 17, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval Sells 11,610 SharesJune 17, 2025 | marketbeat.comAlessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comJay M. Moyes Sells 22,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comAdrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?June 11, 2025 | zacks.comWith 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backingJune 10, 2025 | finance.yahoo.comTwo Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)June 9, 2025 | marketbeat.com78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | businesswire.comMillennium Management LLC Has $5.78 Million Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)May 29, 2025 | marketbeat.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value InvestorsMay 28, 2025 | zacks.comAre Investors Undervaluing Puma Biotechnology (PBYI) Right Now?May 26, 2025 | zacks.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable QualityMay 15, 2025 | uk.finance.yahoo.comDespite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain StockMay 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMURA, NVCT, NLTX, and PBYI Company DescriptionsMural Oncology NASDAQ:MURA$2.48 +0.02 (+0.81%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.48 0.00 (-0.20%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Neoleukin Therapeutics NASDAQ:NLTX$17.20 -0.02 (-0.12%) As of 06/24/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Nuvectis Pharma NASDAQ:NVCT$7.71 -0.03 (-0.39%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$7.70 0.00 (-0.06%) As of 06/26/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Puma Biotechnology NASDAQ:PBYI$3.31 0.00 (0.00%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.38 +0.07 (+1.99%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
